R&D

Located at Sanathnagar, India NATCO's R&D center (NATCO Research Center) built to meet post-GATT requirements, provides a pivotal support to NATCO's operations. With focus on molecular modeling for New Chemical Entities, Phyto Chemistry, Plant Chemistry, New Drug Delivery Technologies - NATCO's Research Centre is at the forefront of the company's strategy to emerge as a research driven organization.

The contribution made by the Research Centre in evolving NATCO as a pioneer contract research organization is invaluable. 

REGULATORY AND OTHERS JOINT RESEARCH PROJECTS BEING UNDERTAKEN 

  Project under going PASTER titled 'Development of Pilot level Anaerobic Treatment Plant for Pharmaceutical     wastes.' 
  Submitted project proposals to the Department of Scientific and Industrial Research under PASTER titled 

 'Synthesis of Novel Drugs for HIV Disorders and AIDS based on CADD studies.

PLANS TOWARDS REGULATORY APPROVALS 

Built State of art facilities for solid dasage forms viz. tablets and capsules & for Metered Dose Inhalers(MDI) and planning for UKMCA,USFDA approvals.


NEW EQUIPMENT BEING ADDED AT PLANTS 

  Fully automated tablet lines for 50 Kg's. and 250 Kg's. with PLC Controls. 
   Fluid bed coating with bottom spray with full computer controls.

PLANS FOR NEW UPGRADATIONS, NEW PLANTS, NEW FACILITIES ETC. 

For future expansions plans are on to create manufacturing facilities for Softgel, Transdermal & upgrade anti-cancer dosage forms manufacturing facility.

PRODUCT AND PROCESS PATENTS GRANTED AND PENDING


NATCO filed patents as per details given below:

API's

24

Natural products

3

New Formulations

9

PCT filing

8

Patents granted

USA

1

INDIA

3

   

PROCESS STABILIZED AND NEW INNOVATIVE PRODUCTS LAUNCHED / TO BE LAUNCHED. 

Process is stabilized and planning to launch new drugs for

  • Anti Cancer and Bone Resorption Preventor.
  • Anti Emetic for Cancer Chemotherapy.
  • Anti Psychotic drugs in control release form.
  • HFA based Metered Dose Inhaler.

Discovery research on New Chemical Entities (NCE) and new drugs delivery technologies. 

Special Data For:-

  • Section V, Appendix - III (Side by side label comparission). 
  • Section V, Appendix - I Package Insert - Celexa. 
  • Section V, Appendix - II ( Package Insert - Citalopram HBr Tablets, 40mg). 
  • Section VIII, Inactive ingredients Vendors CoA & TSE-BSE certificate. 
  • Section VIII, cG MP (TGA) & ISO 14000 certificates. 
  • Section VIII, Drug Substance Manufacturer's Specification, method of Analysis & CoA. 
  • Section VIII, Natco's Drug Substance ( Citalopram HBr ) Specification & Data.
  • Section XII, Appendix - I (b) In-process specification, test method & Certicate of Analysis of Citalopram.
 
NATCO confirms filing of ANDA for Generic Revlimid 31/08/2010
NATCO denies speculative news 23/08/2010
NATCO reports increased earnings and profits 31/07/2010
NATCO launches Anastrazole in the USA 29/06/2010
NATCO records higher sales, profits 25/06/2010
NATCO launches BENDIT 07/04/2010
NATCO declares an interim dividend of Rs. 2 per share 27/01/2010
Press Release 09/01/2010
NATCO records increase in revenues, profits 29/10/2009
Natco’s note on anti-cancer drug Albupax 19/10/2009
NATCO Pharma launches Swine Flu medicine 18/09/2009
NATCO’s partner – Mylan’s – ANDA accepted for review of Glatiramer Acetate 14/09/2009
News | Careers | Privacy Policy
NATCO House, Road No: 2, Banjara Hills, Hyderabad - 500 033
Powered by www.sholay.in